查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462973

脊椎生物製劑市場、佔有率、規模、趨勢、產業分析報告：依產品、最終用戶、地區、細分市場、預測，2024-2032 年

Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，到 2032 年，全球脊椎生物製劑市場預計將達到 31.6 億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

脊椎生物製品市場是由全球醫療支出增加所推動的。 隨著越來越多的資源被分配用於治療退化性椎間盤疾病和椎骨骨折等脊椎疾病，對脊椎生物製劑等創新治療的需求不斷增加。 醫療保健支出的增加將促使脊椎應用的先進生物製劑的研究和開發增加投資，例如骨移植替代品和幹細胞療法。 此外，支出的增加將支持增強 MRI 和 CT 掃瞄等診斷技術的使用，從而促進早期檢測和治療。 採用微創手術技術與脊椎生物製劑結合，為患者提供了傳統手術的微創替代方案，有助於降低成本，同時推動市場成長。

由於脊椎融合手術（通常用於治療退化性椎間盤疾病和椎骨骨折）的應用不斷擴大，脊椎生物製劑市場也在成長。 生物製劑促進骨骼生長並增加脊椎穩定性，使融合手術成功。 生物技術的進步促進了創新脊椎生物製劑的發展，為複雜的脊椎疾病提供了解決方案。 這些產品促進骨再生，改善患者的治療效果並減少額外介入的需要。 隨著人口老化和退化性脊椎疾病的日益流行，對脊椎生物製劑的需求不斷增加。 外科醫生正在將生物製劑納入治療方案，以滿足患者對更好治療結果的期望。 脊椎生物治療應用的監管批准進一步推動了市場擴張並推動脊椎生物製劑市場的成長。

個人化醫療是一種根據遺傳傾向、生活方式和疾病特徵量身訂做治療的方法。 先進的基因測試和生物標記分析使臨床醫生能夠為每位患者選擇最合適的生物製劑，優化療效並最大限度地減少副作用。 此外，個人化醫療促進了針對特定患者亞群定制的新型生物製劑的開發，例如基因治療和精準靶向生物製劑。 醫療保健提供者、研究人員和生物技術公司之間的這種合作將促進脊椎生物製劑的創新，並提供更有效、以患者為中心的治療。

由於經濟的快速成長和醫療基礎設施的改善，新興市場正在為脊椎生物製品市場創造機會。 在亞太、拉丁美洲和中東等地區，隨著老化和城市化導致脊椎疾病盛行率增加，對先進醫療保健的需求不斷增加。 醫療保健支出的增加促進了對創新技術的投資，包括脊椎生物製品。 跨國公司和當地醫療保健提供者之間的合作促進了產品的引入和採用。 這些合作夥伴關係促進知識交流和市場開發，以滿足新興市場不斷變化的醫療保健需求。

脊椎生物製品市場報告亮點

2023年，同種異體脊椎移植領域因其臨床接受度高、療效可靠且疾病傳播風險極低而佔了重要的銷售佔有率。

2023 年，由於全面的護理服務、先進的基礎設施和經驗豐富的醫療保健專業人員，醫院和診所部門佔了很大的銷售佔有率。

2023年，由於先進的醫療基礎設施、脊椎疾病的高盛行率以及完善的監管框架，北美地區佔了主要市場佔有率。

市場遍佈全球，包括 Arthrex, Inc.、Johnson &Johnson、Medtronic plc、NuVasive, Inc.、Organogenesis Inc.、Orthofix Medical Inc.、Stryker Corporation 和 Zimmer Biomet Holdings, Inc.。的存在。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球脊椎生物製劑市場洞察

  • 脊椎生物製品市場 - 產業概況
  • 脊椎生物製劑市場動態
    • 推動者和機會
      • 由於脊椎疾病的發生率不斷增加，對該產品的需求預計會增加。
      • 人們對微創手術的興趣日益濃厚，預計將推動脊椎生物製品市場的成長
    • 抑制因素和課題
      • 治療成本上升可能阻礙市場成長
  • 杵分析
  • 脊椎生物製品產業的趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第 5 章依產品劃分的世界市場

  • 主要發現
  • 簡介
  • 骨移植替代物
  • 同種異體脊椎移植物
  • 其他

第 6 章最終使用者的世界市場

  • 主要發現
  • 簡介
  • 醫院和診所
  • 門診手術中心
  • 其他

第 7 章依地區劃分的世界市場

  • 主要發現
  • 簡介
    • 脊椎生物製品市場評估，地區，2019-2032
  • 脊椎生物製劑市場 - 北美
    • 北美：脊椎生物製劑市場，依最終用戶劃分，2019-2032 年
    • 北美：脊椎生物製品市場（依產品），2019-2032 年
    • 脊椎生物製品市場 - 美國
    • 脊椎生物製品市場 - 加拿大
  • 脊椎生物製劑市場 - 歐洲
    • 歐洲：脊椎生物製劑市場，依最終使用者劃分，2019-2032 年
    • 歐洲：脊椎生物製劑市場（依產品），2019-2032 年
    • 脊椎生物製品市場 - 英國
    • 脊椎生物製品市場 - 法國
    • 脊椎生物製品市場 - 德國
    • 脊椎生物製品市場 - 義大利
    • 脊椎生物製劑市場 - 西班牙
    • 脊椎生物製品市場 - 荷蘭
    • 脊椎生物製劑市場 - 俄羅斯
  • 脊椎生物製劑市場 - 亞太地區
    • 亞太地區：脊椎生物製劑市場，依最終使用者劃分，2019-2032 年
    • 亞太地區：脊椎生物製劑市場（依產品），2019-2032 年
    • 脊椎生物製品市場 - 中國
    • 脊椎生物製劑市場 - 印度
    • 脊椎生物製品市場 - 馬來西亞
    • 脊椎生物製品市場 - 日本
    • 脊椎生物製劑市場 - 印尼
    • 脊椎生物製劑市場 - 韓國
  • 脊椎生物製劑市場 - 中東和非洲
    • 中東和非洲：脊椎生物製品市場，依最終用戶劃分，2019-2032 年
    • 中東和非洲：脊椎生物製劑市場（依產品），2019-2032 年
    • 脊椎生物製品市場 - 沙烏地阿拉伯
    • 脊椎生物製品市場 - 阿聯酋
    • 脊椎生物製品市場 - 以色列
    • 脊椎生物製品市場 - 南非
  • 脊椎生物製劑市場 - 拉丁美洲
    • 拉丁美洲：脊椎生物製劑市場，依最終用戶劃分，2019-2032 年
    • 拉丁美洲：脊椎生物製品市場，依產品，2019-2032 年
    • 脊椎生物製品市場 - 墨西哥
    • 脊椎生物製品市場 - 巴西
    • 脊椎生物製品市場 - 阿根廷

第八章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 合作/協作/合約/出版物

第九章公司簡介

  • Arthrex, Inc
  • Baxter International Inc.
  • Exactech, Inc.
  • Globus Medical Inc.
  • Johnson & Johnson（DePuy Synthes）
  • Kuros Biosciences
  • Medtronic plc
  • NuVasive, Inc.
  • Organogenesis Inc.
  • Orthofix Medical Inc.
  • RTI Surgical Holdings, Inc.
  • SeaSpine Holdings Corporation
  • Spine Wave, Inc.
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
Product Code: PM4665

The global spine biologics market size is expected to reach USD 3.16 billion by 2032, according to a new study by Polaris Market Research. The report "Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The spine biologics market is driven by increasing global healthcare expenditure. With more resources allocated to treating spinal disorders like degenerative disc disease and spinal fractures, demand for innovative treatments such as spine biologics is rising. Higher healthcare spending enables greater investment in research, leading to advanced biologic products tailored for spinal applications like bone graft substitutes and stem cell therapies. Additionally, increased expenditure supports enhanced access to diagnostic technologies like MRI and CT scans, facilitating early detection and treatment. Adoption of minimally invasive surgical techniques, coupled with spine biologics, offers patients less invasive alternatives to traditional surgeries, driving market growth while contributing to cost savings.

The spine biologics market is also growing due to expanding applications in spine fusion procedures, commonly performed for degenerative disc disease and spinal fractures. Biologic products promote bone growth and enhance spinal stability, facilitating successful fusion. Advancements in biotechnology have led to innovative spine biologics, offering solutions for complex spinal conditions. These products stimulate bone regeneration, improving patient outcomes and reducing the need for additional interventions. With an aging population and increasing prevalence of degenerative spine conditions, demand for spine biologics is rising. Surgeons are integrating biologic products into treatment protocols to meet patient expectations for better outcomes. Regulatory approvals for biologic treatments in spinal applications further support market expansion, driving growth in the spine biologics market.

Personalized medicine approaches tailor treatments based on genetic makeup, lifestyle, and disease characteristics. Advanced genetic testing and biomarker analysis enable clinicians to select the most suitable biologic therapies for each patient, optimizing efficacy and minimizing side effects. Additionally, personalized medicine fosters the development of novel biologic treatments, including gene therapies and precision-targeted biologics, customized to specific patient subgroups. This collaborative effort between healthcare providers, researchers, and biotech firms drives innovation in spine biologics, offering more effective and patient-centric treatments.

Emerging markets are fostering opportunities in the spine biologics market owing to rapid economic growth and healthcare infrastructure development. In regions like Asia-Pacific, Latin America, and the Middle East, rising demand for advanced medical treatments accompanies the increasing prevalence of spinal disorders due to aging populations and urbanization. Heightened healthcare expenditure enables investment in innovative technologies, including spine biologics. Collaborations between multinational corporations and local healthcare providers facilitate product introduction and adoption. These partnerships drive knowledge exchange and localized development to meet the evolving healthcare needs of emerging markets.

Spine Biologics Market Report Highlights

In 2023, the spinal allografts segment held a significant revenue share owing to clinical acceptance, proven efficacy, and minimal disease transmission risk.

In 2023, the hospitals and clinics segment held a significant revenue share owing to comprehensive care services, advanced infrastructure, and experienced healthcare professionals.

In 2023, the North America region accounted for a significant market share due to advanced healthcare infrastructure, high prevalence of spinal disorders, and well-established regulatory framework.

The market is highly competitive owing to the existence of market players with a global presence, including Arthrex, Inc., Johnson & Johnson, Medtronic plc, NuVasive, Inc., Organogenesis Inc., Orthofix Medical Inc., Stryker Corporation, and Zimmer Biomet Holdings, Inc. among others.

Polaris Market Research has segmented the Spine Biologics market report based on product, end user, and region:

Spine Biologics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Bone Graft Substitutes
  • Spinal Allografts
  • Others

Spine Biologics, End User Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Spine Biologics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Spine Biologics Market Insights

  • 4.1. Spine Biologics Market - Industry Snapshot
  • 4.2. Spine Biologics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of spinal disorders is projected to spur the product demand
      • 4.2.1.2. Growing preference for minimally invasive procedures is expected to drive spine biologics market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Spine Biologics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Spine Biologics Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Spine Biologics, by Product, 2019-2032 (USD Billion)
  • 5.3. Bone Graft Substitutes
    • 5.3.1. Global Spine Biologics Market, by Bone Graft Substitutes, by Region, 2019-2032 (USD Billion)
  • 5.4. Spinal Allografts
    • 5.4.1. Global Spine Biologics Market, by Spinal Allografts, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Spine Biologics Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 6.3. Hospitals and Clinics
    • 6.3.1. Global Spine Biologics Market, by Hospitals and Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Spine Biologics Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Spine Biologics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Spine Biologics Market - North America
    • 7.3.1. North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.3.2. North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3. Spine Biologics Market - U.S.
      • 7.3.3.1. U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4. Spine Biologics Market - Canada
      • 7.3.4.1. Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4. Spine Biologics Market - Europe
    • 7.4.1. Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3. Spine Biologics Market - UK
      • 7.4.3.1. UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4. Spine Biologics Market - France
      • 7.4.4.1. France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5. Spine Biologics Market - Germany
      • 7.4.5.1. Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6. Spine Biologics Market - Italy
      • 7.4.6.1. Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7. Spine Biologics Market - Spain
      • 7.4.7.1. Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8. Spine Biologics Market - Netherlands
      • 7.4.8.1. Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9. Spine Biologics Market - Russia
      • 7.4.9.1. Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5. Spine Biologics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3. Spine Biologics Market - China
      • 7.5.3.1. China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4. Spine Biologics Market - India
      • 7.5.4.1. India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5. Spine Biologics Market - Malaysia
      • 7.5.5.1. Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6. Spine Biologics Market - Japan
      • 7.5.6.1. Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7. Spine Biologics Market - Indonesia
      • 7.5.7.1. Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8. Spine Biologics Market - South Korea
      • 7.5.8.1. South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6. Spine Biologics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3. Spine Biologics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4. Spine Biologics Market - UAE
      • 7.6.4.1. UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5. Spine Biologics Market - Israel
      • 7.6.5.1. Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6. Spine Biologics Market - South Africa
      • 7.6.6.1. South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7. Spine Biologics Market - Latin America
    • 7.7.1. Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3. Spine Biologics Market - Mexico
      • 7.7.3.1. Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4. Spine Biologics Market - Brazil
      • 7.7.4.1. Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5. Spine Biologics Market - Argentina
      • 7.7.5.1. Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Arthrex, Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Baxter International Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Exactech, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Globus Medical Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Johnson & Johnson (DePuy Synthes)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Kuros Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Medtronic plc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. NuVasive, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Organogenesis Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Orthofix Medical Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. RTI Surgical Holdings, Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. SeaSpine Holdings Corporation
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Spine Wave, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Stryker Corporation
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Zimmer Biomet Holdings, Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables

  • Table 1 Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 2 Global Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 5 North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 6 U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 7 U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 8 Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 9 Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 10 Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 11 Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 12 UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 13 UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 14 France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 15 France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 17 Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 18 Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 19 Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 20 Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 21 Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 24 Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 25 Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 28 China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 29 China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 30 India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 31 India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 35 Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 38 South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 39 South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 44 UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 45 UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 46 Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 47 Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 48 South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 49 South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 51 Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 53 Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 54 Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 55 Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 56 Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 57 Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Spine Biologics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End User
  • Figure 7 Global Spine Biologics Market, by End User, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Product
  • Figure 9 Global Spine Biologics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 10 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Spine Biologics Market